IGC Pharma to Detail Feb. 18 Phase 2 CALMA Trial Progress in Fireside Chat
IGC Pharma CEO Ram Mukunda and CCO Claudia Grimaldi will join Ascendiant Capital Markets for a fireside chat on February 18 at 1:00 p.m. ET. They will discuss Phase 2 CALMA trial enrollment momentum for IGC-AD1 in Alzheimer's agitation, regulatory progress, advancements in the AI-driven precision medicine platform and fiscal 2026 pipeline milestones.
1. Fireside Chat Participation
IGC Pharma announced that CEO Ram Mukunda and CCO Claudia Grimaldi will participate in a live fireside chat hosted by Ascendiant Capital Markets on February 18 at 1:00 p.m. ET, offering investors direct access to senior management insights.
2. Phase 2 CALMA Trial Update
Management will review enrollment momentum in the Phase 2 CALMA trial evaluating IGC-AD1 for agitation associated with Alzheimer’s disease and outline recent regulatory developments affecting trial progression.
3. AI Platform and Pipeline Outlook
The discussion will also cover advancements in IGC Pharma’s AI-driven precision medicine platform, progress on disease-modifying candidates such as TGR-63 targeting amyloid plaques, and strategic priorities and milestones planned for fiscal 2026.